The world's largest and most experienced group of its kind, supporting strategic drug development decisions and submission-ready analyses.
“Pharsight was a key partner in the development of Soliris® (eculizumab) as a treatment for patients with atypical Hemolytic-Uremic Syndrome (aHUS). Recent FDA and CHMP approvals mark an important advance for patients suffering from this ultra-rare, life-threatening genetic disease. We especially appreciated Pharsight’s contributions to the dosing strategy based on Phase II data and the accompanying submission dossier. Their professional insights, sustained efforts and diligence were important contributions to this successful effort on behalf of patients in the US and EU."
Stephen P. Squinto, Ph.D.
Executive Vice President and
Head of Research & Development
Alexion Pharmaceuticals, Inc.